

0003-approved

Professional information for SEASONEZE

SCHEDULING STATUS

S1

1. NAME OF THE MEDICINE

SEASONEZE 10 mg film-coated tablets

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Each film-coated tablet contains 10 mg cetirizine dihydrochloride.

Excipients with known effect:

Contains sugar: Each tablet contains 66,4 mg lactose monohydrate.

For full list of excipients, see section 6.1.

3. PHARMACEUTICAL FORM

Film-coated tablets.

SEASONEZE tablets are white to off white, round, film-coated tablets scored on the one side and plain on the other.

4. CLINICAL PARTICULARS

4.1 Therapeutic indications

Allergic processes responding to a histamine H₁ receptor antagonist.

- Respiratory: Allergic rhinitis, hay fever.
- Cutaneous: Allergic skin conditions associated with pruritus e.g. urticaria.

4.2 Posology and method of administration

Adults and children 12 years of age or older: one 10 mg tablet daily

0003-approved

Children aged 6 to 12 years: 10 mg (one tablet) once daily or 5 mg (half a tablet) twice daily.

Special populations:

Elderly patients:

At present there are no data to suggest that the dose needs to be reduced in elderly patients with normal renal function.

Dosage in renal impairment:

In patients with renal insufficiency (creatinine clearance less than 40 mL/min), the dosage should be reduced to half the usual recommended dose.

Dosage in hepatic impairment:

Half the recommended daily dose should be used in patients with moderate to severe hepatic impairment.

Method of administration:

Oral administration.

Missed dose:

Doctors should advise patients who forget to take SEASONEZE to take a dose as soon as possible and then to continue with the normal dose. Patients should not take a double dose to compensate for the missed dose.

Paediatric population

Not suitable for children less than 6 years of age.

0003-approved**4.3 Contraindications**

- Hypersensitivity to cetirizine, to any of the excipients (see section 6.1), to hydroxyzine or to any piperazine derivatives.
- Patients with severe renal impairment at less than 30 mL/min creatinine clearance.
- Asthma, as it may cause airway obstruction in patients who have previously experienced adverse reactions to antihistamines.
- Pregnancy and lactation, as safety has not been established.
- Children under the age of two years, as safety and efficacy have not been demonstrated.

4.4 Special warnings and precautions for use

Caution should be taken in patients with predisposition factors of urinary retention (e.g. spinal cord lesion, prostatic hyperplasia) as SEASONEZE may increase the risk of urinary retention.

Porphyria: Use with caution.

SEASONEZE lacks significant sedative effects. Patients should be warned however that a small number of individuals may experience sedation.

At therapeutic doses, no clinically significant interactions have been demonstrated with alcohol (for a blood alcohol level of 0,5 g/L). Nevertheless, precaution is recommended if alcohol is taken concomitantly.

Caution is recommended when SEASONEZE is used in epileptic patients and patients at risk of convulsions.

Response to allergy skin tests is inhibited by antihistamines and a wash-out period (of 3 days) is required before performing them.

0003-approved

Pruritus and/or urticaria may occur when SEASONEZE is stopped, even if those symptoms were not present before treatment initiation. In some cases, the symptoms may be intense and may require treatment to be restarted. The symptoms should resolve when the treatment is restarted.

SEASONEZE contains lactose. Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption should not take SEASONEZE.

Paediatric population

The use of SEASONEZE is not recommended in children aged less than 6 years since this formulation does not allow for appropriate dose adaptation. It is recommended to use a paediatric formulation of cetirizine.

4.5 Interaction with other medicines and other forms of interaction

Due to the pharmacokinetic, pharmacodynamic and tolerance profile of cetirizine, no interactions are expected with this antihistamine.

Actually, neither pharmacodynamic nor significant pharmacokinetic interaction was reported in interactions studies performed, notably with pseudoephedrine or theophylline (400 mg/day).

The extent of absorption of cetirizine is not reduced with food, although the rate of absorption is decreased.

In sensitive patients, the concurrent use of alcohol or other central nervous system (CNS) depressants may cause additional reductions in alertness and impairment of performance, although cetirizine does not potentiate the effect of alcohol (0,5 g/L blood levels) (see section 4.4).

4.6 Fertility, pregnancy and lactation

Pregnancy

0003-approved

Safety and efficacy in pregnancy and lactation has not been established (see section 4.3).

Prospectively collected data on pregnancy outcomes do not suggest potential for maternal or foetal/embryonic toxicity above background rates.

Animal studies do not indicate direct or indirect harmful effects with respect to pregnancy, embryonal/fetal development, parturition or postnatal development. SEASONEZE should not be used during pregnancy.

Breastfeeding

Cetirizine is excreted in breast milk. Cetirizine is excreted in human milk at concentrations representing 25 % to 90 % those measured in plasma, depending on sampling time after administration. SEASONEZE should not be used when breastfeeding.

Fertility

Limited data is available on human fertility, but no safety concern has been identified. Animal data show no safety concern for human reproduction.

4.7 Effects on ability to drive and use machines

Patients should be warned that some individuals may experience sedation. It is therefore advisable to determine individual response before driving a vehicle or operating machinery. This effect may be compounded by the simultaneous intake of alcohol or other central nervous system depressants (see section 4.5).

4.8 Undesirable effects

SEASONEZE at the recommended dosage has minor adverse effects on the CNS, including somnolence, fatigue, dizziness and headache. In some cases, paradoxical CNS stimulation has been reported.

0003-approved

SEASONEZE is a selective antagonist of peripheral H₁-receptors and is relatively free of anticholinergic activity. Nevertheless, cases of micturition difficulties, eye accommodation disorders and dry mouth have been reported following the use of SEASONEZE.

Instances of abnormal hepatic function with elevated hepatic enzymes accompanied by elevated bilirubin have been reported following the use of SEASONEZE. This may resolve upon discontinuation of the medicine.

Clinical trials

Double blind controlled clinical trials comparing cetirizine to placebo or other antihistamines at the recommended dosage (10 mg daily for cetirizine), of which quantified safety data are available, included more than 3 200 subjects exposed to cetirizine.

The following adverse reactions were reported:

Blood and the lymphatic system disorders

Less frequent: leucopenia, haemolytic anaemia, agranulocytosis

Psychiatric disorders

Frequent: somnolence

Nervous system disorders

Frequent: dizziness, headache

Ear and labyrinth disorders

Less frequent: tinnitus

Cardiac disorders

0003-approved

Less frequent: palpitations, dysrhythmias

Vascular disorders:

Less frequent: hypotension

Respiratory, thoracic and mediastinal disorders

Frequent: pharyngitis, rhinitis, thickening of mucous, bronchospasm

Gastrointestinal disorders

Frequent: dry mouth, nausea

Less frequent: abdominal pain, constipation

Hepato-biliary disorders

Less frequent: jaundice

Skin and subcutaneous tissue disorders

Less frequent: photosensitivity, hair loss, sweating

General disorders and administration site conditions

Frequent: fatigue

Somnolence was mild to moderate in the majority of cases.

Objective tests as demonstrated by other studies have demonstrated that usual daily activities are unaffected at the recommended daily dose in healthy young volunteers.

Post-marketing experience

0003-approved

In addition to the adverse reactions reported during clinical studies and listed above, the following undesirable effects have been reported in post-marketing experience.

Blood and the lymphatic system disorders

Less frequent: thrombocytopenia

Immune system disorders

Less frequent: hypersensitivity, anaphylactic shock

Metabolism and nutrition disorders

Less frequent: increased appetite

Psychiatric disorders

Less frequent: agitation, aggression, confusion, depression, hallucination, insomnia, tics

Frequency unknown: suicidal ideation, nightmare

Nervous system disorders

Less frequent: paraesthesia, convulsions, dysgeusia, dyskinesia, dystonia, syncope, tremor, drowsiness, anxiety, nervousness

Frequency unknown: amnesia, memory impairment, movement disorder

Eye disorders

Less frequent: accommodation disorder, blurred vision, oculogyration

Ear and labyrinth disorders

Frequency unknown: vertigo

0003-approved

Cardiac disorders

Less frequent: tachycardia

Gastrointestinal disorders

Less frequent: diarrhoea, gastrointestinal discomfort

Hepatobiliary disorders

Less frequent: abnormal hepatic function (increased transaminases, alkaline phosphatase, γ -GT and bilirubin)

Frequency unknown: hepatitis

Skin and subcutaneous tissue disorders

Less frequent: pruritis, rash, urticaria, angioneurotic oedema, fixed drug eruption

Frequency unknown: acute generalized exanthematous pustulosis

Musculoskeletal and connective tissue disorders

Frequency unknown: arthralgia, myalgia

Renal and urinary disorders

Less frequent: dysuria, enuresis

Frequency unknown: urinary retention

General disorders and administrative site conditions

Less frequent: asthenia, malaise, oedema

Investigations

Less frequent: increased weight

0003-approved***Description of selected adverse reactions***

After discontinuation of SEASONEZE, pruritus (intense itching) and/or urticaria have been reported.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicine is important. It allows continued monitoring of the benefit/risk balance of the medicine. Health care providers are asked to report any suspected adverse reactions via the Med Safety APP (Medsafety X SAHPRA) and eReporting platform (who-umc.org) found on SAHPRA website.

4.9 Overdose***Symptoms of overdose***

Symptoms observed after an overdose of SEASONEZE are mainly associated with CNS effects or with effects that could suggest an anticholinergic effect.

Adverse events reported are: confusion, diarrhoea, dizziness, fatigue, headache, malaise, mydriasis, pruritis, restlessness, sedation, somnolence, stupor, tachycardia, tremor, and urinary retention.

Management

There is no known specific antidote to SEASONEZE.

Should overdose occur, symptomatic or supportive treatment is recommended. SEASONEZE is not effectively removed by dialysis.

5. PHARMACOLOGICAL PROPERTIES**5.1 Pharmacodynamic properties**

Category and class: A 5.7.1 Medicines affecting autonomic function. Antihistaminics

0003-approved

Pharmacotherapeutic group: Antihistamine for systemic use, piperazine derivatives,

ATC code: R06A E07.

Cetirizine is a metabolite of hydroxyzine. It is a non-sedating reversible, competitive inhibitor of histamine at the histamine-1 (H_1) receptor, devoid of any significant anticholinergic and antiserotonergic effects. The anti-allergic activity seems to be exerted primarily via effects on the release of mediators such as histamine. Cetirizine inhibits the late phase recruitment of eosinophils, in the skin and conjunctiva of atopic subjects submitted to allergen challenge.

5.2 Pharmacokinetic properties

Absorption

After oral administration, cetirizine is well absorbed from the gastrointestinal tract and peak plasma concentrations are reached within 1 hour. The steady state peak plasma concentrations is approximately 300 ng/mL. The distribution of pharmacokinetic parameters such as peak plasma concentration (C_{max}) and area under curve (AUC), is unimodal. Food decreases the rate but not the extent of absorption.

Distribution

The apparent volume of distribution is 0,50 L/kg. Cetirizine is highly bound to plasma proteins, however does not modify the protein binding of warfarin.

Biotransformation

Cetirizine is only marginally affected by first pass metabolism in the liver.

Elimination

0003-approved

The terminal half-life is approximately 10 hours in adults. Cetirizine is excreted primarily (60 %)

unchanged in the urine. No accumulation is observed for cetirizine following daily doses of 10 mg for 10 days.

Linearity/Non-linearity

Pharmacokinetics are linear with plasma concentrations increasing proportionately with increasing doses.

Special populations

Renal impairment

The pharmacokinetics of cetirizine was similar in patients with mild impairment (creatinine clearance higher than 40 mL/min) and healthy volunteers. Patients with moderate renal impairment had a 3-fold increase in half-life and 70 % decrease in clearance compared to healthy volunteers. Patients on hemodialysis (creatinine clearance less than 7 mL/min) given a single oral 10 mg dose of cetirizine had a 3-fold increase in half-life and a 70 % decrease in clearance compared to patients with normal renal function. Cetirizine was poorly cleared by haemodialysis. Dosing adjustment is necessary in patients with renal impairment (see section 4.2).

Hepatic impairment

Patients with chronic liver diseases (hepatocellular, cholestatic, and biliary cirrhosis) given 10 or 20 mg of cetirizine as a single dose had a 50 % increase in half-life along with a 40 % decrease in clearance compared to healthy subjects.

Elderly

Following a single 10 mg oral dose, half-life increased by about 50 % and clearance decreased by 40 % in 16 elderly subjects compared to younger subjects. The decrease in cetirizine clearance in these elderly volunteers appeared to be related to their decreased renal function.

0003-approved

Paediatric population

The half-life of cetirizine was about 6 hours in children of 6 – 12 years and 5 hours in children 2 – 6 years.

6. PHARMACEUTICAL PARTICULARS

6.1 List of excipients

Tablet core:

Colloidal anhydrous silica

Lactose monohydrate

Magnesium stearate

Microcrystalline cellulose.

Film-coating:

Opadry White Y-1-7000 (consisting of hypromellose (E646), titanium dioxide (E171) and polyethylene glycol 400 (E1521)).

6.2 Incompatibilities

Not applicable.

6.3 Shelf life

24 months.

6.4 Special precautions for storage

Store at or below 25 °C.

0003-approved

6.5 Nature and contents of container

SEASONEZE tablets are available in white plastic bottles, patient ready packs or in clear plastic/silver aluminium blister packs containing 10, 20, 28, 30, 120 or 500 tablets.

6.6 Special precautions for disposal and other handling

No special requirements.

7. HOLDER OF CERTIFICATE OF REGISTRATION

Biotech Laboratories (Pty) Ltd
Ground Floor, Block K West, Central Park
400 16th Road, Randjespark, Midrand 1685
South Africa

8. REGISTRATION NUMBER

37/5.7.1/0086

9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

Date of registration: 02 July 2007

10. DATE OF REVISION OF THE TEXT

19 February 2025